First AD

Second AD

John Chan, MD, is a volunteer clinical professor of obstetrics/gynecology, Reproductive Sciences, in the UCSF School of Medicine, as well as director of Gynecologic Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center.

Optimizing PARP Inhibitor Duration

Video content above is prompted by the following:

How long do you typically continue PARPi in the first-line setting? Does this differ in the second-line setting?

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Advancements in the Management of Ovarian Cancer 

OncLive Insights

Panelists discuss how the duration of PARP inhibitor (PARPi) therapy typically differs between the first-line and second-line settings in advanced ovarian cancer treatment.